Company Name: Villeroy & Boch ISIN: DE0007657231   Reason for the research: Update Recommendation: Buy from: 04.08.2025 Target price: 34.50 Last rating change: Analyst: Ralf Marinoni H1-25 development: no major surprise In the H1-25 period, Villeroy & Boch's sales grew by 12.1% to EUR 725.8m as a result of acquisitions. A [ … ]

Company Name: Formycon AG ISIN: DE000A1EWVY8   Reason for the research: Update Recommendation: Buy from: 04.08.2025 Target price: €49 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]

Company Name: The Platform Group AG ISIN: DE000A2QEFA1   Reason for the research: Update Recommendation: Buy from: 04.08.2025 Target price: 19,00 Euro Target price on sight of: 12 months Last rating change: - Analyst: Alexander Rihane First Berlin Equity Research hat ein Research Update zu The Platform Group AG (ISIN: DE000A2QEF [ … ]

Company Name: ZEAL Network SE ISIN: DE000ZEAL241   Reason for the research: Update Recommendation: BUY from: 04.08.2025 Target price: EUR 64.00 Target price on sight of: 12 months Last rating change: Analyst: Henry Wendisch Games business to gain more traction. ZEAL should have made further progress on the games portfolio roll [ … ]

Company Name: Westwing Group SE ISIN: DE000A2N4H07   Reason for the research: Update Recommendation: Buy from: 04.08.2025 Target price: EUR 18.00 Target price on sight of: 12 months Last rating change: Analyst: Henry Wendisch Rising share of own products as gross margin driver. As a direct result of the assortment change, the  [ … ]

ProSiebenSat.1 Media’s (PSM) Q2 2025 results were again clouded by weakness in its high-margin TV advertising (ad) business, given persistent macro headwinds. Revenues declined 7% yoy (a 1% miss vs consensus; -3% yoy organic), due to soft ad revenues. Adj. EBITDA dropped 40% yoy to EUR 55m, posting a 13% miss, also in part due to Verivox deconsolidation. Management expects recovery in Entertainment ad revenues in DACH in H2 and broadly maintained its FY 2025 outlook – revenues of c. EUR 3.85bn (+/- EUR 150m) and adj. EBITDA of EUR 520m (+/- EUR 50m), however, now below mid-point of the target range. Following PPF Group’s offer to increase its stake in PSM to 29.99% for cash of EUR 7.00/share, MFE-MediaForEurope enhanced its public takeover offer for all outstanding PSM shares. MFE is now offering cash of EUR 4.48+ 1.3 MFE A-shares per PSM share (initial offer: cash: EUR 4.48+ 0.4 MFE A-shares), translating to c. EUR 8.15/ share. PPF’s offer just increases its stake; however, the MFE proposal means ceding full control. We revise our target price to EUR 8.00 (old: EUR 7.00), converging to MFE’s new offer and maintain our HOLD rating on the stock. The full update can be downloaded under https://research-hub.de/companies/prosiebensat-1-media-se

Nemetschek (NEM) reported detailed Q2 2025 results that were in line with its preliminary release. The revenue momentum continued to impress, led by increasing share of subscription and SaaS revenues (+72.5% yoy in constant currencies [c.c.]). The overall Q2 topline grew 30.5% yoy c.c. on strong organic (org.) growth of 21.6% yoy in c.c. The Build segment continued to grow organically and through contribution from GoCanvas, while Design benefitted from growing demand for multi-year subscription contracts. EBITDA increased 44.0% yoy to EUR 88.5m in Q2, with margins expanding 3.5ppt yoy to 30.5% on operating leverage benefits. Following a strong H1, management had raised its FY 2025 guidance at the time of pre-release, which it confirmed. It estimates revenues to grow by 20%-22% yoy c.c. (+17%-19% previously) and the EBITDA margin is still forecasted at c.31%. High annual recurring revenue share provides good business stability and enhances margin quality. Execution is strong with growing presence in the US, but valuation appears fair. We reiterate HOLD rating at an unchanged PT of EUR 125.00. The full update can be downloaded under https://research-hub.de/companies/nemetschek-se

Wacker Chemie’s final Q2 2025 results confirmed its preliminary numbers. Sales declined by 4% yoy in Q2 on weak prices and volumes, and EBITDA fell by a steep 26% yoy, due to sub-optimal utilization rates. In particular, Polymers and Polysilicon reported sharp deterioration in their operating performance. End-market demand remains weak, macro and tariff uncertainties cloud visibility, and FX headwinds are increasing for global chemical players. In its recently slashed FY 2025 guidance, Wacker expects to report broadly steady sales yoy while close the year with an EBITDA which is lower anywhere between 6% to 33% yoy, clearly indicating to the unpredictable outlook. To counter the secular challenges, Wacker is realigning its business to less-cyclical industries, cutting costs, and adopting a disciplined capex policy. We see the current valuation as a chance to add exposure to the medium-term recovery story. We maintain our PT at EUR 85.00 and reiterate our BUY rating. The full update can be downloaded under https://research-hub.de/companies/wacker-chemie-ag

Ceconomy has entered into an investment agreement with JD.com, which will launch a voluntary public takeover offer at EUR 4.60 per share, representing a 43% premium over the three-month average price. Anchor shareholders, controlling about 32% of shares, have committed to the offer, with Convergenta retaining around 25.4%. JD.com intends to preserve Ceconomy’s operational independence, leveraging its advanced technology and logistics to support digitalization and growth, while existing management and brands remain intact for at least five years. A delisting is planned post-takeover. With strong shareholder backing and a fair offer, completion is highly likely; shareholders are advised to tender. The full update can be downloaded under https://research-hub.de/companies/ceconomy-ag

Bayer's Q2 2025 preliminaries reflect strong operational execution, with EBITDA before special items materially ahead of consensus and full-year currency-adjusted guidance raised, driven by Pharmaceuticals and Crop Science resilience. However, this positive momentum is overshadowed by a substantial increase in US litigation provisions, alongside persistently modest free cash flow and elevated net financial debt. With the shares now trading close to our fair value of EUR 29.00, we downgrade from BUY to HOLD, as ongoing legal and financial uncertainties constrain near-term upside despite improved underlying trends. We remain selective pending greater visibility on legal risks. The full update can be downloaded under https://research-hub.de/companies/bayer-ag